{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:21:00Z","timestamp":1791091260732,"version":"4.1.0"},"reference-count":172,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca"},{"name":"Merck & Co."},{"name":"Accumetrics"},{"name":"Eli Lilly and Company\/Daiichi Sankyo"},{"name":"sanofi-aventis\/Regeneron"},{"name":"Bristol-Myers Squibb"},{"name":"Iroko Pharmaceuticals"},{"name":"Medscape"},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.jcin.2013.06.011","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T01:09:43Z","timestamp":1384996183000},"page":"1111-1128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"title":["Response Variability to P2Y12 Receptor Inhibitors"],"prefix":"10.1016","volume":"6","author":[{"given":"Jolanta M.","family":"Siller-Matula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Trenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Schr\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinrad","family":"Gawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen D.","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2013.06.011_bib1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/nm1102-1227","article-title":"Platelets in atherothrombosis","volume":"8","author":"Ruggeri","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/ncpcardio1372","article-title":"Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future","volume":"5","author":"Raju","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0037-1616220","article-title":"ADP receptors of platelets and their inhibition","volume":"86","author":"Gachet","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1476-5381.2009.00555.x","article-title":"Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disease","volume":"159","author":"Siller-Matula","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcin.2013.06.011_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2125.2006.02792.x","article-title":"A\u00a0multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans","volume":"63","author":"Jakubowski","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jcin.2013.06.011_bib6","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.011_bib7","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.011_bib8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/dc08-2064","article-title":"Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions","volume":"32","author":"Angiolillo","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcin.2013.06.011_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1538-7836.2007.02812.x","article-title":"The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score","volume":"6","author":"Geisler","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib10","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2011.1529","article-title":"Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis","volume":"306","author":"Cayla","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2013.06.011_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1741-7015-9-3","article-title":"Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance\u2014the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy","volume":"9","author":"Neubauer","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","article-title":"Calcium-channel blockers reduce the antiplatelet effect of clopidogrel","volume":"52","author":"Siller-Matula","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1160\/TH09-08-0516","article-title":"The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response","volume":"103","author":"Harmsze","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib14","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib15","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1111\/j.1538-7836.2011.04483.x","article-title":"Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention","volume":"9","author":"Harmsze","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2009.05.050","article-title":"Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study","volume":"54","author":"Cuisset","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib18","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1111\/j.1538-7836.2010.04049.x","article-title":"Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis","volume":"8","author":"Siller-Matula","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib19","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.ahj.2008.09.017","article-title":"Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel","volume":"157","author":"Siller-Matula","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib20","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of\u00a0CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib21","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/eurheartj\/ehq321","article-title":"CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study","volume":"31","author":"Harmsze","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jcin.2010.05.007","volume":"3","author":"Jeong","year":"2010","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2013.06.011_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/eurheartj\/ehp402","article-title":"Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions","volume":"31","author":"Geisler","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1538-7836.2009.03699.x","article-title":"Multiple electrode aggregometry predicts stent thrombosis better than the VASP assay","volume":"8","author":"Siller-Matula","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib26","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2007.01.094","article-title":"Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis","volume":"49","author":"Buonamici","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib27","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1161\/CIRCULATIONAHA.109.883454","article-title":"High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease","volume":"120","author":"Migliorini","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.011_bib28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jacc.2008.05.032","article-title":"Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents","volume":"52","author":"Gori","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib29","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjcard.2009.06.007","article-title":"Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients","volume":"104","author":"Cuisset","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/09537100802351065","article-title":"Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target","volume":"19","author":"Gurbel","year":"2008","journal-title":"Platelets"},{"key":"10.1016\/j.jcin.2013.06.011_bib31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1160\/TH06-07-0362","article-title":"High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes","volume":"97","author":"Cuisset","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2005.08.058","article-title":"Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance","volume":"47","author":"Lev","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib33","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jacc.2008.10.045","volume":"53","author":"Gurbel","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2013.06.011_bib35","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2006.06.065","article-title":"Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement","volume":"48","author":"Hochholzer","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib36","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.amjcard.2011.08.034","article-title":"Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel","volume":"109","author":"Parodi","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib37","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/01.CIR.0000157138.02645.11","article-title":"Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study","volume":"111","author":"Gurbel","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.011_bib38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2012.04639.x","article-title":"Phenotyping versus genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study","volume":"10","author":"Siller-Matula","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2010.03.048","article-title":"Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window","volume":"56","author":"Sibbing","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","article-title":"Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement","volume":"8","author":"Sibbing","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib41","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ahj.2010.02.025","article-title":"Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation","volume":"159","author":"Eshtehardi","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib42","first-page":"16","article-title":"Assessment of platelet response with multiplate impedance aggregometry in patients with coronary stents on clopidogrel and aspirin treatment","volume":"17","author":"Dineva","year":"2011","journal-title":"Kardiologia"},{"key":"10.1016\/j.jcin.2013.06.011_bib43","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/eurheartj\/ehn046","article-title":"Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation","volume":"29","author":"Price","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib44","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2008.06.038","volume":"52","author":"Patti","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib45","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.amjcard.2008.02.054","article-title":"Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris","volume":"101","author":"Cuisset","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib46","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1160\/TH11-02-0077","article-title":"Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay\u00a0in clinical routine for prediction of postprocedural major adverse cardiovascular events","volume":"106","author":"Freynhofer","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2011.04.017","article-title":"High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes","volume":"58","author":"Bonello","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib48","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib49","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH07-04-0296","article-title":"ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome","volume":"98","author":"Frere","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib50","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jacc.2006.10.050","article-title":"Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?","volume":"49","author":"Bliden","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jtcvs.2004.02.019","article-title":"Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting","volume":"128","author":"Chen","year":"2004","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jcin.2013.06.011_bib52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1160\/TH07-07-0478","article-title":"Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment","volume":"99","author":"Sibbing","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/09537100802657735","article-title":"Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM","volume":"20","author":"Scharbert","year":"2009","journal-title":"Platelets"},{"key":"10.1016\/j.jcin.2013.06.011_bib54","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1160\/TH06-05-0242","article-title":"Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood","volume":"96","author":"Toth","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib55","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1399-6576.2008.01845.x","article-title":"Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry","volume":"53","author":"Rahe-Meyer","year":"2009","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jcin.2013.06.011_bib56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.athoracsur.2010.09.022","article-title":"Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines","volume":"91","author":"Ranucci","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jcin.2013.06.011_bib57","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1160\/TH07-09-0575","article-title":"The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y(12) inhibition levels following prasugrel and clopidogrel administration","volume":"99","author":"Jakubowski","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib58","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2013.06.011_bib59","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.2012.17312","article-title":"Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy","volume":"308","author":"Gurbel","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2013.06.011_bib60","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib61","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","author":"Campo","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","article-title":"Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up","volume":"119","author":"Marcucci","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.011_bib63","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1160\/TH06-08-0420","article-title":"Thienopyridines in cardiovascular disease: focus on clopidogrel resistance","volume":"97","author":"Siller-Matula","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib64","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1160\/TH07-05-0324","article-title":"The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis","volume":"98","author":"Blindt","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib65","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/09537100802272634","article-title":"Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay","volume":"19","author":"Siller-Matula","year":"2008","journal-title":"Platelets"},{"key":"10.1016\/j.jcin.2013.06.011_bib66","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","article-title":"Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases","volume":"3","author":"Aleil","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","article-title":"Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis","volume":"103","author":"Bonello","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib68","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/j.1538-7836.2007.02609.x","article-title":"Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events","volume":"5","author":"Bonello","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib69","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1160\/TH11-09-0623","article-title":"Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: does standardisation matter?","volume":"107","author":"Freynhofer","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib70","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1538-7836.2011.04604.x","article-title":"High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low?","volume":"10","author":"Jeong","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib71","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jcin.2010.03.003","article-title":"Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry","volume":"3","author":"El Ghannudi","year":"2010","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2013.06.011_bib72","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1067\/mlc.2001.117406","article-title":"Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction","volume":"138","author":"Jilma","year":"2001","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib73","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.05.001","article-title":"Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients","volume":"16","author":"Kotzailias","year":"2007","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jcin.2013.06.011_bib74","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/09537100801989857","article-title":"Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100","volume":"19","author":"Madsen","year":"2008","journal-title":"Platelets"},{"key":"10.1016\/j.jcin.2013.06.011_bib75","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1160\/TH09-08-0527","article-title":"A\u00a0comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease","volume":"103","author":"Grove","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib76","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.thromres.2005.10.011","article-title":"Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study","volume":"118","author":"Gianetti","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.jcin.2013.06.011_bib77","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1538-7836.2006.02239.x","article-title":"Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS","volume":"4","author":"Fuchs","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib78","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ejim.2011.02.021","article-title":"Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention","volume":"22","author":"Chiu","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib79","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/j.1538-7836.2008.03112.x","article-title":"Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI","volume":"6","author":"Campo","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib80","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1537-2995.2007.01070.x","article-title":"Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytometry and a cone and plate(let) analyzer (Impact-R)","volume":"47","author":"Panzer","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.jcin.2013.06.011_bib81","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1055\/s-0038-1649720","article-title":"Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp","volume":"70","author":"Varon","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib82","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1423-0410.2007.00938.x","article-title":"Use of the DiaMed Impact R to test platelet function in stored platelet concentrates","volume":"93","author":"Morrison","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.jcin.2013.06.011_bib83","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.lab.2004.01.011","article-title":"A\u00a0novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation","volume":"143","author":"Craft","year":"2004","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib84","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2013.06.011_bib85","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2013.06.011_bib86","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","article-title":"Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis","volume":"56","author":"Hulot","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib87","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib88","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jacc.2010.04.008","article-title":"Genotyping: one piece of the puzzle to personalize antiplatelet therapy","volume":"56","author":"Gurbel","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib89","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ahj.2010.12.011","article-title":"The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy","volume":"161","author":"Gurbel","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib90","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCINTERVENTIONS.111.963025","article-title":"CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients","volume":"4","author":"Hulot","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2013.06.011_bib91","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis","volume":"103","author":"Giusti","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib92","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib93","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2013.06.011_bib94","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehs059","article-title":"The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study","author":"Bhatt","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib95","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib96","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCINTERVENTIONS.111.962555","article-title":"Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin","volume":"4","author":"Jeong","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2013.06.011_bib97","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1538-7836.2009.03500.x","article-title":"The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome","volume":"7","author":"Frere","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib98","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.011_bib99","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on\u00a0outcomes of clopidogrel treatment","volume":"363","author":"Pare","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib100","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2013.06.011_bib101","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib102","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","article-title":"Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.011_bib103","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehr155","article-title":"No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting","volume":"32","author":"Sibbing","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib104","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/CIRCGENETICS.111.960112","article-title":"Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement","volume":"4","author":"Trenk","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jcin.2013.06.011_bib105","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/clpt.2011.193","article-title":"Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction","volume":"90","author":"Simon","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2013.06.011_bib106","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCINTERVENTIONS.111.965400","article-title":"No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting","volume":"5","author":"Jaitner","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2013.06.011_bib107","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1538-7836.2011.04457.x","article-title":"Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention","volume":"9","author":"Campo","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib108","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1472-8206.2011.00986.x","article-title":"Pharmacokinetic basis of the\u00a0antiplatelet action of prasugrel","volume":"26","author":"Schror","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jcin.2013.06.011_bib109","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.011_bib110","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib111","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2217\/fca.10.89","article-title":"Ticagrelor: from discovery to phase III clinical trial","volume":"6","author":"Siller-Matula","year":"2010","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib112","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib113","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehp159","article-title":"Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial","volume":"30","author":"Michelson","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib114","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2013.06.011_bib116","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ahj.2011.07.026","article-title":"Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel","volume":"162","author":"Alexopoulos","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib117","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1538-7836.2011.04531.x","article-title":"Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and high on-treatment platelet reactivity","volume":"9","author":"Alexopoulos","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib118","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/eurheartj\/ehl489","article-title":"A\u00a0double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days","volume":"28","author":"von Beckerath","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib119","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","article-title":"Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease","volume":"50","author":"Angiolillo","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1160\/TH07-09-0562","article-title":"Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study","volume":"99","author":"Angiolillo","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib121","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jcin.2008.09.004","article-title":"Clopidogrel 150 mg\/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study","volume":"1","author":"Aleil","year":"2008","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2013.06.011_bib122","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacc.2008.12.025","volume":"53","author":"Jeong","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib123","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jcin.2011.03.002","article-title":"High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)","author":"Collet","year":"2011","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2013.06.011_bib124","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jcin.2010.12.010","article-title":"Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype","volume":"4","author":"Kim","year":"2011","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2013.06.011_bib125","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study","volume":"51","author":"Bonello","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib126","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ijcard.2012.05.040","article-title":"Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study","volume":"167","author":"Siller-Matula","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib127","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/CIRCULATIONAHA.108.833236","volume":"119","author":"Valgimigli","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.011_bib128","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jcin.2008.08.018","article-title":"Glycoprotein IIb\/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study","volume":"1","author":"Cuisset","year":"2008","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2013.06.011_bib129","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.011_bib130","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib131","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.ijcard.2012.05.100","article-title":"Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis","volume":"167","author":"Aradi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib132","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1160\/TH11-05-0346","article-title":"Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity","volume":"106","author":"Capranzano","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib133","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.thromres.2008.04.003","article-title":"Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response","volume":"123","author":"Cuisset","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.jcin.2013.06.011_bib134","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijcard.2012.01.016","article-title":"Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin","volume":"167","author":"Siller-Matula","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.amjcard.2007.02.081","article-title":"Impact of body mass index on platelet aggregation after\u00a0administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention","volume":"100","author":"Sibbing","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib136","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1538-7836.2010.04063.x","article-title":"Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study","volume":"8","author":"Fontana","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib137","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2009.06.049","article-title":"A\u00a0comparison of clopidogrel responsiveness in patients with versus without chronic renal failure","volume":"104","author":"Park","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib138","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/14622416.9.9.1251","article-title":"CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation","volume":"9","author":"Geisler","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jcin.2013.06.011_bib139","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00392-010-0179-x","article-title":"Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions","volume":"99","author":"Geisler","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib140","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jacc.2008.04.045","article-title":"The association of cigarette smoking with enhanced platelet inhibition by clopidogrel","volume":"52","author":"Bliden","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib141","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/j.thromres.2010.03.020","article-title":"Smoking at least 10 cigarettes per\u00a0day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction","volume":"126","author":"Jeong","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jcin.2013.06.011_bib142","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/09537100903046317","article-title":"Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects","volume":"20","author":"Li","year":"2009","journal-title":"Platelets"},{"key":"10.1016\/j.jcin.2013.06.011_bib143","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1160\/TH09-05-0285","article-title":"The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests","volume":"102","author":"Elsenberg","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib144","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jacc.2008.05.054","article-title":"Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel","volume":"52","author":"Ang","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib145","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1160\/TH10-05-0266","article-title":"Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment","volume":"104","author":"Bernlochner","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib146","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/hrt.2010.195438","article-title":"Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"97","author":"Siller-Matula","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jcin.2013.06.011_bib147","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.amjcard.2010.10.045","article-title":"Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation","volume":"107","author":"Quadros","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib148","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcin.2013.06.011_bib149","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1538-7836.2010.03921.x","article-title":"Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy","volume":"8","author":"Sibbing","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib150","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1161\/01.ATV.0000223867.25324.1a","article-title":"Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel","volume":"26","author":"Angiolillo","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcin.2013.06.011_bib151","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/dmd.31.1.53","article-title":"The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin","volume":"31","author":"Clarke","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jcin.2013.06.011_bib152","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.0000112378.09325.F9","article-title":"Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance","volume":"109","author":"Lau","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.011_bib153","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1503\/cmaj.060664","article-title":"Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel","volume":"174","author":"Suh","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.jcin.2013.06.011_bib154","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cca.2011.10.018","article-title":"Increased clopidogrel response is associated with ABCC3 expression: a pilot study","volume":"413","author":"Luchessi","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jcin.2013.06.011_bib155","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jacc.2011.02.040","article-title":"Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease","volume":"58","author":"Angiolillo","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib156","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/eurheartj\/ehq023","article-title":"Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel","volume":"31","author":"Sibbing","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib157","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.clpt.6100139","article-title":"Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently","volume":"81","author":"Farid","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2013.06.011_bib158","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.jacc.2005.07.056","article-title":"Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib159","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1538-7836.2005.01751.x","article-title":"High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome","volume":"4","author":"Cuisset","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2013.06.011_bib160","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2008.10.007","article-title":"Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent","volume":"124","author":"Wang","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.jcin.2013.06.011_bib161","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.jacc.2005.01.058","article-title":"Stent thrombosis is associated with an impaired response to antiplatelet therapy","volume":"45","author":"Wenaweser","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib162","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3174\/ajnr.A0917","article-title":"Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting","volume":"29","author":"M\u00fcller-Schunk","year":"2008","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib163","first-page":"295","article-title":"Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation","volume":"59","author":"Barragan","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2013.06.011_bib164","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.jacc.2011.08.057","article-title":"A\u00a0Point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after\u00a0drug-eluting stent implantation","volume":"58","author":"Park","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.011_bib165","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/hrt.2010.220491","article-title":"High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention","volume":"97","author":"Breet","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jcin.2013.06.011_bib166","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4244\/51","article-title":"Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?","volume":"5","author":"Cuisset","year":"2009","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2013.06.011_bib167","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.thromres.2010.01.013","article-title":"Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention","volume":"126","author":"Mokhtar","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jcin.2013.06.011_bib168","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/hrt.2011.227272","article-title":"Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents","volume":"98","author":"Oh","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jcin.2013.06.011_bib169","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib170","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ahj.2010.06.039","article-title":"Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events","volume":"160","author":"Tiroch","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2013.06.011_bib171","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1253\/circj.CJ-10-0525","article-title":"Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel","volume":"75","author":"Sawada","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.jcin.2013.06.011_bib172","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/FPC.0b013e32834ff6e3","article-title":"The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting","volume":"22","author":"Harmsze","year":"2012","journal-title":"Pharmacogenet Genomics"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879813013526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879813013526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:59:49Z","timestamp":1761847189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879813013526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":172,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1936879813013526"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2013.06.011","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response Variability to P2Y12 Receptor Inhibitors","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2013.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}